General Information of Drug (ID: DMS5ICY)

Drug Name
10,11-dihydro-5H-dibenzo[b,f]azepine Drug Info
Synonyms
Iminodibenzyl; 494-19-9; 10,11-Dihydro-5H-dibenzo[b,f]azepine; 10,11-Dihydro-5H-dibenz[b,f]azepine; Iminobibenzyl; 2,2'-Iminodibenzyl; 2,2'-Iminobibenzyl; 5H-Dibenz[b,f]azepine, 10,11-dihydro-; RP 23669; UNII-262BX7OE3U; NSC 72110; 10,11-Dihydro-5-dibenz(b,f)azepine; 6,11-dihydro-5H-benzo[b][1]benzazepine; 10,11-Dihydrodibenz(b,f)azepine; EINECS 207-787-1; 10,11-Dihydro-5H-dibenz(b,f)azepine; BRN 0152732; CHEMBL63054; 5H-Dibenz(b,f)azepine, 10,11-dihydro-; AI3-39165; 262BX7OE3U; ZSMRRZONCYIFNB-UHFFFAOYSA-N
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10308
CAS Number
CAS 494-19-9
TTD Drug ID
DMS5ICY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting 5-HT 3A receptor (HTR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolasetron DMMG26Z Nausea MD90 Approved [2]
Alosetron DML2A03 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [3]
Tropisetron DMNSJ7V Fibromyalgia MG30.01 Approved [4]
Palonosetron DMBHMOX Nausea MD90 Approved [5]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [4]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [6]
Cilansetron DMP0NGX Irritable bowel syndrome DD91.0 Phase 3 [7]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [8]
Norcisapride DMJSKUI Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [9]
YM-114 DML2IXO Nausea MD90 Discontinued in Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Inhibitor [1]

References

1 Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors. Eur J Med Chem. 2009 Jun;44(6):2667-72.
2 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
3 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
4 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
5 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
6 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
7 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
8 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
9 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
10 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.